Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study

  • The PLOS ONE Staff
  • Article
  • Metrics
  • Comments
  • Media Coverage

There is an error in Table 2. The values for Plasma YKL-40 in the Multivariate PFS column and the Multivariate OS column are incorrect. The author has provided a corrected table here.

thumbnail
Download:
Table 2. Univariate and multivariate Cox analyses of PFS and OS in 510 patients with mCRC included in the Nordic VII Study according to pretreatment plasma YKL-40 and clinical parameters. All treatment groups are combined.

https://doi.org/10.1371/journal.pone.0087746.t002

There are also several errors in the third sentence of the “Changes in plasma YKL-40 and serum CEA during treatment and efficacy” section of the Results, including an incorrect P-value for the high-serum CEA. The correct sentence is: In contrast, short PFS was not associated with high plasma YKL-40 (continuous variable; HR  =  1.06; 95% CI 0.96-1.17; P  =  0.28) but with high serum CEA (HR  =  1.08; 95% CI 1.03-1.13; P  =  0.0026).

Reference

  1. 1. Tarpgaard LS, Guren TK, Glimelius B, Christensen IJ, Pfeiffer P, et al. (2014) Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study. PLoS ONE 9(2): e87746

Citation: The PLOS ONE Staff (2014) Correction: Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study. PLoS ONE 9(5): e98836. https://doi.org/10.1371/journal.pone.0098836

Published: May 22, 2014

Copyright: © 2014 The PLOS ONE Staff. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.